Christopher H. Lowrey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher H. Lowrey has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Michael J. Nemeth
4 shared publicationsRachel J. West
Department of Medicine
2 shared publicationsCatherine J Ackley
Hinman Box 7650, Department of Pharmacology & Toxicology, Dartmouth Medical School, Hanover, NH 03755-1404, USA
1 shared publicationCatherine J. Ackley
Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03756, USA
1 shared publicationChristine A. Richardson
Medicine
1 shared publicationDavid M. Bodine
Hematopoiesis Section, Genetics and Molecular Biology Branch, NHGRI, National Institutes of Health, Bethesda, Maryland, 20892
1 shared publication
Latest Publications
- Open Access
- 31 January 2013
- Published by American Society of Hematology in Blood
- Vol. 121 (5) , 830-839
Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells
Key Points: Simvastatin and tBHQ suppress KLF1 and BCL11 gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Because both drugs are FDA-approved, these findings could lead to clinical trials in the relatively near future.
- 31 January 2013
- Published by American Society of Hematology in Blood
- Vol. 121 (5) , 830-839
Open AccessSimvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells
Key Points: Simvastatin and tBHQ suppress KLF1 and BCL11 gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Because both drugs are FDA-approved, these findings could lead to clinical trials in the relatively near future.
- Open Access
- 15 August 2007
- Published by American Society of Hematology in Blood
- Vol. 110 (4) , 1343-1352
Developmental- and differentiation-specific patterns of human γ- and β-globin promoter DNA methylation
The mechanisms underlying the human fetal-to-adult β-globin gene switch remain to be determined. While there is substantial experimental evidence to suggest that promoter DNA methylation is involved in this process, most data come from studies in nonhuman systems. We have evaluated human γ- and β-globin promoter methylation in primary human fetal liver (FL) and adult bone marrow (ABM) erythroid cells. Our results show that, in general, promoter methylation and gene expression are inversely related. However, CpGs at −162 of the γ promoter and −126 of the β promoter are hypomethylated in ABM and FL, respectively. We also studied γ-globin promoter methylation during in vitro differentiation of erythroid cells. The γ promoters are initially hypermethylated in CD34+ cells. The upstream γ promoter CpGs become hypomethylated during the preerythroid phase of differentiation and are then remethylated later, during erythropoiesis. The period of promoter hypomethylation correlates with transient γ-globin gene expression and may explain the previously observed fetal hemoglobin production that occurs during early adult erythropoiesis. These results provide the first comprehensive survey of developmental changes in human γ- and β-globin promoter methylation and support the hypothesis that promoter methylation plays a role in human β-globin locus gene switching.
- 15 August 2007
- Published by American Society of Hematology in Blood
- Vol. 110 (4) , 1343-1352
Open AccessDevelopmental- and differentiation-specific patterns of human γ- and β-globin promoter DNA methylation
The mechanisms underlying the human fetal-to-adult β-globin gene switch remain to be determined. While there is substantial experimental evidence to suggest that promoter DNA methylation is involved in this process, most data come from studies in nonhuman systems. We have evaluated human γ- and β-globin promoter methylation in primary human fetal liver (FL) and adult bone marrow (ABM) erythroid cells. Our results show that, in general, promoter methylation and gene expression are inversely related. However, CpGs at −162 of the γ promoter and −126 of the β promoter are hypomethylated in ABM and FL, respectively. We also studied γ-globin promoter methylation during in vitro differentiation of erythroid cells. The γ promoters are initially hypermethylated in CD34+ cells. The upstream γ promoter CpGs become hypomethylated during the preerythroid phase of differentiation and are then remethylated later, during erythropoiesis. The period of promoter hypomethylation correlates with transient γ-globin gene expression and may explain the previously observed fetal hemoglobin production that occurs during early adult erythropoiesis. These results provide the first comprehensive survey of developmental changes in human γ- and β-globin promoter methylation and support the hypothesis that promoter methylation plays a role in human β-globin locus gene switching.
- 6 December 2006
- Published by Elsevier in Journal of Molecular Biology
- Vol. 366 (3) , 737-744
Expression of GATA-1 in a Non-hematopoietic Cell Line Induces β-Globin Locus Control Region Chromatin Structure Remodeling and an Erythroid Pattern of Gene Expression
- 6 December 2006
- Published by Elsevier in Journal of Molecular Biology
- Vol. 366 (3) , 737-744
Expression of GATA-1 in a Non-hematopoietic Cell Line Induces β-Globin Locus Control Region Chromatin Structure Remodeling and an Erythroid Pattern of Gene Expression
- 1 December 2004
- Vol. 8, 475-486
An Erythroid-Specific Chromatin Opening Element Increases β-Globin Gene Expression from Integrated Retroviral Gene Transfer Vectors.
Gene therapy strategies requiring long-term high-level expression from integrated genes are currently limited by inconsistent levels of expression. This may be observed as variegated, silenced or position-dependent gene expression. Each of these phenomena involve suppressive chromatin structures. We hypothesized that by actively conferring an open chromatin structure on integrated vectors would increase transgene expression. To test this idea we used a 100bp element from the β-globin locus control region (LCR) which is able to independently open local chromatin structure in erythroid tissues. This element includes binding sites for GATA-1, NF-E2, EKLF and Sp-1 and is evolutionarily conserved. We constructed a series of MSCV-based vectors containing the β-globin gene driven by a minimal β-globin promoter with combinations of the HSFE and LCR derived enhancer elements. Pools of MEL clones containing integrated vectors were analyzed for chromatin structure and β-globin gene expression. The HSFE increased the extent of nuclease sensitive chromatin over the promoters of the constructs. The most effective vector included tandem copies of the HSFE and produced a 5-fold increase in expression compared to the promoter alone. These results indicate that the HSFE is able to augment the opening of β-globin promoter chromatin structure and significantly increase gene expression in the context of an integrated retroviral vector.
- 1 December 2004
- Vol. 8, 475-486
An Erythroid-Specific Chromatin Opening Element Increases β-Globin Gene Expression from Integrated Retroviral Gene Transfer Vectors.
Gene therapy strategies requiring long-term high-level expression from integrated genes are currently limited by inconsistent levels of expression. This may be observed as variegated, silenced or position-dependent gene expression. Each of these phenomena involve suppressive chromatin structures. We hypothesized that by actively conferring an open chromatin structure on integrated vectors would increase transgene expression. To test this idea we used a 100bp element from the β-globin locus control region (LCR) which is able to independently open local chromatin structure in erythroid tissues. This element includes binding sites for GATA-1, NF-E2, EKLF and Sp-1 and is evolutionarily conserved. We constructed a series of MSCV-based vectors containing the β-globin gene driven by a minimal β-globin promoter with combinations of the HSFE and LCR derived enhancer elements. Pools of MEL clones containing integrated vectors were analyzed for chromatin structure and β-globin gene expression. The HSFE increased the extent of nuclease sensitive chromatin over the promoters of the constructs. The most effective vector included tandem copies of the HSFE and produced a 5-fold increase in expression compared to the promoter alone. These results indicate that the HSFE is able to augment the opening of β-globin promoter chromatin structure and significantly increase gene expression in the context of an integrated retroviral vector.
- 1 January 2003
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 3 (8) , 1279-1289
Defensive applications of gene transfer technology in the face of bioterrorism: DNA-based vaccines and immune targeting
Gene transfer involves the introduction of an engineered gene into a person’s cells with the expectation that the protein expressed from the gene will produce a therapeutic benefit. Strategies based on this principle have led to the approval of > 600 clinical trials and enrolment of ∼ 3500 subjects worldwide in attempts to treat diseases ranging from cancer to AIDS to cystic fibrosis. While gene therapy has met with limited success and still has many hurdles to overcome before it sees wide application, it may be useful as a defensive strategy against bioterrorism agents including infectious microbes and toxins. Although many defensive strategies are possible, immunological strategies are currently the most developed and are being actively applied to the development of strategies against several of the most virulent potential bioweapons. While most of these strategies are not yet ready for human application, DNA-based vaccines appear to be among the most promising in the fight against bioterrorism.
- 1 January 2003
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 3 (8) , 1279-1289
Defensive applications of gene transfer technology in the face of bioterrorism: DNA-based vaccines and immune targeting
Gene transfer involves the introduction of an engineered gene into a person’s cells with the expectation that the protein expressed from the gene will produce a therapeutic benefit. Strategies based on this principle have led to the approval of > 600 clinical trials and enrolment of ∼ 3500 subjects worldwide in attempts to treat diseases ranging from cancer to AIDS to cystic fibrosis. While gene therapy has met with limited success and still has many hurdles to overcome before it sees wide application, it may be useful as a defensive strategy against bioterrorism agents including infectious microbes and toxins. Although many defensive strategies are possible, immunological strategies are currently the most developed and are being actively applied to the development of strategies against several of the most virulent potential bioweapons. While most of these strategies are not yet ready for human application, DNA-based vaccines appear to be among the most promising in the fight against bioterrorism.
- 1 July 2001
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 27 (4) , 767-780
An Erythroid-Specific Chromatin Opening Element Reorganizes β-Globin Promoter Chromatin Structure and Augments Gene Expression
- 1 July 2001
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 27 (4) , 767-780
An Erythroid-Specific Chromatin Opening Element Reorganizes β-Globin Promoter Chromatin Structure and Augments Gene Expression
- 1 January 2000
- Vol. 4 (5) , 437-455
Erythropoiesis: Review Article: Slow and Steady Wins The Race? Progress in the Development of Vectors for Gene Therapy of beta-Thalassemia and Sickle Cell Disease.
The cloning of the human beta-globin genes more than 20 years ago led to predictions that beta-thalassemia and sickle cell disease would be among the first monogenic diseases to be successfully treated by gene replacement therapy. However, despite the world-wide enrollment of more than 3,000 patients in approved gene transfer protocols, none have involved therapy for these diseases. This has been due to several technical hurdles that need to be overcome before gene replacement therapy for beta-thalassemia and sickle cell disease can become practical. These problems include inefficient transduction of hematopoietic stem cells and an inability to achieve consistent, long-term, high-level expression of transferred beta-like globin genes with current gene transfer vectors. In this review we highlight the relationships between understanding the fundamental mechanisms of beta-globin gene locus function and basic vector biology and the development of strategies for beta-globin gene replacement therapy. Despite slow initial progress in this field, recent advances in a variety of critical areas provide hope that clinical trials may not be far away.
- 1 January 2000
- Vol. 4 (5) , 437-455
Erythropoiesis: Review Article: Slow and Steady Wins The Race? Progress in the Development of Vectors for Gene Therapy of beta-Thalassemia and Sickle Cell Disease.
The cloning of the human beta-globin genes more than 20 years ago led to predictions that beta-thalassemia and sickle cell disease would be among the first monogenic diseases to be successfully treated by gene replacement therapy. However, despite the world-wide enrollment of more than 3,000 patients in approved gene transfer protocols, none have involved therapy for these diseases. This has been due to several technical hurdles that need to be overcome before gene replacement therapy for beta-thalassemia and sickle cell disease can become practical. These problems include inefficient transduction of hematopoietic stem cells and an inability to achieve consistent, long-term, high-level expression of transferred beta-like globin genes with current gene transfer vectors. In this review we highlight the relationships between understanding the fundamental mechanisms of beta-globin gene locus function and basic vector biology and the development of strategies for beta-globin gene replacement therapy. Despite slow initial progress in this field, recent advances in a variety of critical areas provide hope that clinical trials may not be far away.
- 1 January 1999
- Published by Taylor & Francis in Hematology
- Vol. 4 (5) , 437-455
Slow and Steady Wins The Race? Progress in the Development of Vectors for Gene Therapy of β -Thalassemia and Sickle Cell Disease
The cloning of the human β-globin genes more than 20 years ago led to predictions that β-thalassemia and sickle cell disease would be among the first monogenic diseases to be successfully treated by gene replacement therapy. However, despite the worldwide enrollment of more than 3,000 patients in approved gene transfer protocols, none have involved therapy for these diseases. This has been due to several technical hurdles that need to be overcome before gene replacement therapy for β-thalassemia and sickle cell disease can become practical. These problems include inefficient transduction of hematopoietic stem cells and an inability to achieve consistent, long-term, high-level expression of transferred β-like globin genes with current gene transfer vectors. In this review we highlight the relationships between understanding the fundamental mechanisms of β-globin gene locus function and basic vector biology and the development of strategies for β-globin gene replacement therapy. Despite slow initial progress in this field, recent advances in a variety of critical areas provide hope that clinical trials may not be far away.
- 1 January 1999
- Published by Taylor & Francis in Hematology
- Vol. 4 (5) , 437-455
Slow and Steady Wins The Race? Progress in the Development of Vectors for Gene Therapy of β -Thalassemia and Sickle Cell Disease
The cloning of the human β-globin genes more than 20 years ago led to predictions that β-thalassemia and sickle cell disease would be among the first monogenic diseases to be successfully treated by gene replacement therapy. However, despite the worldwide enrollment of more than 3,000 patients in approved gene transfer protocols, none have involved therapy for these diseases. This has been due to several technical hurdles that need to be overcome before gene replacement therapy for β-thalassemia and sickle cell disease can become practical. These problems include inefficient transduction of hematopoietic stem cells and an inability to achieve consistent, long-term, high-level expression of transferred β-like globin genes with current gene transfer vectors. In this review we highlight the relationships between understanding the fundamental mechanisms of β-globin gene locus function and basic vector biology and the development of strategies for β-globin gene replacement therapy. Despite slow initial progress in this field, recent advances in a variety of critical areas provide hope that clinical trials may not be far away.